107 related articles for article (PubMed ID: 19933079)
1. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
Yardley DA; Burris HA; Markus T; Spigel DR; Greco FA; Mainwaring M; Waterhouse DM; Webb CD; Hainsworth JD
Clin Breast Cancer; 2009 Nov; 9(4):237-42. PubMed ID: 19933079
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.
Yardley DA; Burris HA; Spigel DR; Clark BL; Vazquez E; Shipley D; Barton J; Thompson D; Montes I; Greco FA; Hainsworth JD
Clin Breast Cancer; 2009 Nov; 9(4):247-52. PubMed ID: 19933081
[TBL] [Abstract][Full Text] [Related]
5. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer.
Maass N; Schem C; Bauerschlag DO; Tiemann K; Schaefer FW; Hanson S; Muth M; Baier M; Weigel MT; Wenners AS; Alkatout I; Bauer M; Jonat W; Mundhenke C
Oncology; 2014; 87(5):300-10. PubMed ID: 25171229
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
7. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
9. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Huang CH; Williamson SK; Van Veldhuizen PJ; Hsueh CT; Allen A; Tawfik O; Wick J; Smith H; Uypeckcuat AM; Mayo M; Kelly K
J Thorac Oncol; 2011 Feb; 6(2):372-7. PubMed ID: 21178640
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
15. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Chew HK; Barlow WE; Albain K; Lew D; Gown A; Hayes DF; Gralow J; Hortobagyi GN; Livingston R
Clin Breast Cancer; 2008 Dec; 8(6):511-5. PubMed ID: 19073506
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Trent JC; Valero V; Booser DJ; Esparza-Guerra LT; Ibrahim N; Rahman Z; Vernillet L; Patel S; David CL; Murray JL; Cristofanilli M; Hortobagyi GN
Clin Cancer Res; 2003 Jul; 9(7):2426-34. PubMed ID: 12855614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
